Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 28.87 Million SEK | 9492.11% |
| 2022 | 266 Thousand SEK | -81.58% |
| 2021 | 1.44 Million SEK | 136.99% |
| 2020 | -3.89 Million SEK | 69.38% |
| 2019 | -13.63 Million SEK | -162.09% |
| 2018 | 17.21 Million SEK | 147.44% |
| 2017 | 8.27 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 24.38 Million SEK | 247.42% |
| 2024 Q1 | -17.34 Million SEK | -533.9% |
| 2023 Q2 | 11.44 Million SEK | 44.09% |
| 2023 Q1 | 7.94 Million SEK | -48.86% |
| 2023 FY | - SEK | 9492.11% |
| 2023 Q4 | 3.63 Million SEK | -33.69% |
| 2023 Q3 | 5.48 Million SEK | -52.09% |
| 2022 Q2 | -13.66 Million SEK | -920.24% |
| 2022 Q1 | -1.33 Million SEK | -112.16% |
| 2022 FY | - SEK | -81.58% |
| 2022 Q4 | 15.53 Million SEK | 993.04% |
| 2022 Q3 | -1.73 Million SEK | 87.27% |
| 2021 Q1 | -7.8 Million SEK | -288.8% |
| 2021 Q2 | -541 Thousand SEK | 93.07% |
| 2021 Q4 | 11.01 Million SEK | 1823.16% |
| 2021 Q3 | -639 Thousand SEK | -18.11% |
| 2021 FY | - SEK | 136.99% |
| 2020 Q4 | 4.13 Million SEK | -6.49% |
| 2020 Q3 | 4.42 Million SEK | 147.01% |
| 2020 Q2 | -9.4 Million SEK | -4578.11% |
| 2020 Q1 | -201 Thousand SEK | -101.87% |
| 2020 FY | - SEK | 69.38% |
| 2019 FY | - SEK | -162.09% |
| 2019 Q4 | 10.75 Million SEK | 260.77% |
| 2019 Q3 | -6.68 Million SEK | 32.0% |
| 2019 Q2 | -9.83 Million SEK | -15.81% |
| 2019 Q1 | -8.49 Million SEK | -135.72% |
| 2018 Q2 | -3.46 Million SEK | -338.56% |
| 2018 Q3 | 1.34 Million SEK | 138.77% |
| 2018 Q4 | 23.77 Million SEK | 1667.66% |
| 2018 FY | - SEK | 147.44% |
| 2018 Q1 | -791 Thousand SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 137.438% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 92.99% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 92.99% |
| Arcoma AB | 6.24 Million SEK | -362.116% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 132.088% |
| BICO Group AB (publ) | 322.3 Million SEK | 91.042% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 56.239% |
| CellaVision AB (publ) | 207.24 Million SEK | 86.068% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 142.208% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 203.328% |
| C-Rad AB (publ) | 48.9 Million SEK | 40.96% |
| Duearity AB (publ) | -24.77 Million SEK | 216.522% |
| Dignitana AB (publ) | -264 Thousand SEK | 11036.742% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 132.922% |
| Getinge AB (publ) | 5.92 Billion SEK | 99.513% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 142.934% |
| Iconovo AB (publ) | -35.33 Million SEK | 181.711% |
| Integrum AB (publ) | 8.76 Million SEK | -229.543% |
| Luxbright AB (publ) | -23.86 Million SEK | 220.976% |
| OssDsign AB (publ) | -122.02 Million SEK | 123.662% |
| Paxman AB (publ) | 31.22 Million SEK | 7.544% |
| Promimic AB (publ) | -3.68 Million SEK | 883.741% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 119.184% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 155.708% |
| ScandiDos AB (publ) | -13.35 Million SEK | 316.18% |
| Sectra AB (publ) | 615.06 Million SEK | 95.306% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 155.875% |
| Senzime AB (publ) | -118.82 Million SEK | 124.299% |
| SpectraCure AB (publ) | -20.96 Million SEK | 237.694% |
| Stille AB | 56.04 Million SEK | 48.479% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 100.907% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 77.189% |